NeOnc Technologies Holdings is trading 6.61% up in pre-market at $5.00, versus $4.69 at the August 28, 2026 close; no new company-specific announcement was identified for August 31.

  • Earlier positive NEO100 Phase 2a results showed 48.9% six-month progression-free survival versus a 20% benchmark.
  • The company plans an FDA Type B meeting, but available coverage does not directly connect these developments to today’s pre-market move.